Cilnidipine Metoprolol Tablet

# CILROOT-XL25

**Cilnidipine 10 mg & Metoprolol Succinate Extended Release 25 mg Tablets**

**Division: DIABGLYM**

## Composition

Each extended-release tablet contains:

* Cilnidipine IP — 10 mg

* Metoprolol Succinate Extended Release IP equivalent to Metoprolol — 25 mg

* Excipients — q.s.

* Colour: Approved colour used

**Dosage Form:** Extended-release oral tablet

## Product Description

CILROOT-XL25 is a balanced antihypertensive combination of **Cilnidipine 10 mg and Metoprolol Succinate Extended Release 25 mg**, formulated for the management of hypertension and cardiovascular conditions requiring both blood pressure and heart-rate control.

Cilnidipine provides sustained arterial vasodilation through dual L-type and N-type calcium channel blockade, while Metoprolol Succinate ER provides sustained beta-1 selective blockade. Together, they offer complementary mechanisms for blood pressure control and reduction of cardiac workload.

CILROOT-XL25 may be considered for patients with hypertension associated with tachycardia, coronary artery disease, diabetes, metabolic syndrome, or those requiring combination antihypertensive therapy, as determined by the treating physician.

## Technical Knowledge

**Cilnidipine** blocks L-type calcium channels in vascular smooth muscle and N-type calcium channels associated with sympathetic nerve terminals. This promotes vasodilation, reduces peripheral vascular resistance, and helps modulate sympathetic activity.

**Metoprolol Succinate ER** selectively blocks beta-1 adrenergic receptors, reducing sympathetic stimulation, heart rate, myocardial contractility, cardiac output, and renin release. The extended-release formulation provides sustained therapeutic activity.

The combination therefore addresses both **vascular resistance and cardiac sympathetic activity**, providing complementary antihypertensive action.

## Mechanism of Action

**Cilnidipine:** Blocks L-type and N-type calcium channels → vascular relaxation → reduced peripheral vascular resistance → blood pressure reduction.

**Metoprolol Succinate ER:** Selective beta-1 blockade → reduced heart rate and myocardial contractility → reduced cardiac workload and myocardial oxygen demand.

## Key Benefits

* Effective reduction of elevated blood pressure

* Dual-mechanism antihypertensive therapy

* Sustained blood pressure control

* Helps control elevated heart rate

* Reduces cardiac workload

* Reduces myocardial oxygen demand

* Modulates sympathetic activity

* Convenient combination therapy

* Suitable for long-term cardiovascular management under medical supervision

## Clinical Applications

CILROOT-XL25 may be prescribed for:

* Essential hypertension

* Hypertension with tachycardia

* Hypertension with coronary artery disease

* Hypertension associated with diabetes

* Cardiovascular risk management

* Patients requiring combination antihypertensive therapy

## Key Facts

* **Cilnidipine 10 mg** provides vascular calcium-channel blockade.

* **Metoprolol Succinate ER 25 mg** provides sustained beta-1 selective blockade.

* Combines vascular and cardiac mechanisms.

* Designed for sustained cardiovascular control.

* Suitable for individualized antihypertensive therapy under physician supervision.

* Quality-assured pharmaceutical formulation.

## PCD Pharma Franchise Opportunity

CILROOT-XL25 is a suitable addition to **PCD Pharma Franchise, Cardiology Franchise, and Cardio-Diabetic Franchise** portfolios across India. The growing demand for combination antihypertensive therapies creates significant prescription and market potential.

### Why Choose CILROOT-XL25?

* Strong therapeutic segment

* Combination formulation

* Broad physician potential

* Competitive commercial opportunity

* Attractive monopoly franchise potential

* Promotional support

* Visual aid and marketing support

* Consistent product quality

* Potential for repeat business

## Third Party Manufacturing

**Chemsroot Pharmaceutical** offers Third Party Manufacturing of Cilnidipine 10 mg and Metoprolol Succinate Extended Release 25 mg Tablets for pharmaceutical companies, marketers, exporters, and franchise businesses.

### Manufacturing Services

* Private label manufacturing

* Contract manufacturing

* Custom brand manufacturing

* Loan license manufacturing

* GMP-compliant production

* Batch manufacturing documentation

* Product registration support

* Customized packaging and artwork

* Monopoly franchise packaging

* Bulk manufacturing capability

### Manufacturing Features

* Pharmaceutical-grade raw materials

* In-process quality control

* Finished product testing

* Stability-oriented extended-release formulation

* Controlled-release manufacturing technology

* Blister and Alu-Alu packaging options

**CILROOT-XL25 from DIABGLYM** combines sustained antihypertensive action, heart-rate control, and complementary cardiovascular therapy, making it a valuable formulation for physicians, cardiologists, diabetologists, PCD Pharma Franchise partners, and Third Party Manufacturing clients.